Separating Epigenetic Signals Improves Early Cancer Detection with Rob Osborne, Biomodal

About this episode

Rob Osborne discusses how separating epigenetic signals can enhance early cancer detection.

We’ve gotten very good at reading DNA. We’re just beginning to understand how to read its state. On today’s show, Rob Osborne, Senior Vice President of R&D at Biomodal, discusses new evidence that separating two epigenetic marks—5-methylcytosine and 5-hydroxymethylcytosine—can improve early cancer detection from liquid biopsy. In a recent Nature Communications Medicine study, his team showed that analyzing these signals independently in circulating DNA significantly enhanced detection of Stage I colorectal cancer compared with approaches that combine them. The advance does not require new sequencing hardware. Biomodal’s approach uses a sample preparation kit compatible with existing platforms, paired with bioinformatics tools, potentially lowering the barrier to adoption while expanding the information content of standard sequencing workflows. The underlying insight is biological as much as technical. Most methylation assays collapse 5mC and 5hmC into a single signal, masking early transitions in gene regulation. Osborne describes this as “squishing them into one output,” a simplification that can obscure meaningful changes in disease onset and progression. By separating the…

People in this episode

Host: Theral Timpson

Guest: Rob Osborne

Topics covered

• epigenetics
• cancer detection
• liquid biopsy
• methylation
• gene regulation

Keywords

• epigenetic marks
• 5-methylcytosine
• 5-hydroxymethylcytosine
• Stage I colorectal cancer
• circulating DNA

Mentioned in this episode

Organizations: Biomodal

Books & works: Nature Communications Medicine

More episodes of Mendelspod Podcast

• Gary Schroth on Connecting Cellular Behavior to the Transcriptome · June 11, 2026 · 33 min
• Two-Thirds of High-Risk Breast Cancer Patients May Avoid Chemotherapy According to Veracyte Data Presented at ASCO · June 9, 2026 · 27 min
• Building the Diagnostic Layer of Modern Cancer Care with Rita Shaknovich and Karina Kulangara of Agilent · May 29, 2026 · 32 min
• Mapping the Multi-Omic Era with Eric Green of Illumina · May 28, 2026 · 44 min
• Inside Proteomics at Thermo Fisher with Yan Zhang · May 21, 2026 · 5 min
• Digital Controls for Cancer Drug Trials? Irina Babina, Concr · May 15, 2026 · 4 min